substantia nigra neuron
Recently Published Documents


TOTAL DOCUMENTS

7
(FIVE YEARS 0)

H-INDEX

4
(FIVE YEARS 0)

2017 ◽  
Vol 43 (7) ◽  
pp. 621-630 ◽  
Author(s):  
R. D. Abbott ◽  
J. S. Nelson ◽  
G.W. Ross ◽  
J. H. Uyehara-Lock ◽  
C. M. Tanner ◽  
...  

Neurology ◽  
2015 ◽  
Vol 86 (6) ◽  
pp. 512-519 ◽  
Author(s):  
Robert D. Abbott ◽  
G. Webster Ross ◽  
Helen Petrovitch ◽  
Kamal H. Masaki ◽  
Lenore J. Launer ◽  
...  

2008 ◽  
Vol 24 (3) ◽  
pp. 371-376 ◽  
Author(s):  
Helen Petrovitch ◽  
Robert D. Abbott ◽  
G. Webster Ross ◽  
James Nelson ◽  
Kamal H. Masaki ◽  
...  

2005 ◽  
Vol 26 (1) ◽  
pp. 56-62 ◽  
Author(s):  
Xiao-chun CHEN ◽  
Yi-can ZHOU ◽  
Ying CHEN ◽  
Yuan-gui ZHU ◽  
Fang FANG ◽  
...  

2004 ◽  
Vol 56 (4) ◽  
pp. 532-539 ◽  
Author(s):  
G. Webster Ross ◽  
Helen Petrovitch ◽  
Robert D. Abbott ◽  
James Nelson ◽  
William Markesbery ◽  
...  

1995 ◽  
Vol 18 (1) ◽  
pp. 63-65 ◽  
Author(s):  
Elliott J. Mufson ◽  
Teresa Sobreviela

AbstractStein & Glasier suggest embryonic neural tissue grafts as a potential treatment strategy for Alzheimer's and Parkinson's disease. As an alternative, we suggest that the family of nerve growth factor-related neurotrophins and their trk (tyrosine kinase) receptors underlie cholinergic basal forebrain (CBF) and dopaminergic substantia nigra neuron degeneration in these diseases, respectively. Therefore, treatment approaches for these disorders could utilize neurotrophins.


Sign in / Sign up

Export Citation Format

Share Document